Gilead Research Highlights at CROI 2023 in Seattle
Explore the latest research presented by Gilead at CROI 2023 in Seattle, featuring abstracts on HIV treatment response predictors, long-acting Lenacapavir, F/TAF outcomes, HIV prevention, and exciting progress in HIV cure research. Don't miss the insightful findings and promising developments in the
0 views • 16 slides
Resistance Analysis of Long-Acting Lenacapavir in HIV Treatment: 104-Week Findings
Study on long-acting lenacapavir in heavily treatment-experienced HIV individuals after 104 weeks revealed emergence of lenacapavir resistance-associated mutations. Lenacapavir, a potent HIV-1 capsid inhibitor, has shown activity against ARV-resistant strains. The CAPELLA study analyzed lenacapavir
0 views • 11 slides
Gilead-Supported Abstracts Published at CROI 2021: Treatment Updates and Lenacapavir Advancements
Abstracts from CROI 2021 selected by Gilead highlight treatment effects on neurologic outcomes, drug interactions, clinical trials of antiretroviral therapy, and new developments in drug resistance. Additionally, the session on Lenacapavir (GS-6207) presents promising data on this long-acting HIV ca
0 views • 13 slides